

---

**BOB CHAMPION CANCER TRUST**

---

**UNAUDITED**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 30 JUNE 2020**

---

**BOB CHAMPION CANCER TRUST**

---

---

**CONTENTS**

---

	Page
<b>Reference and administrative details of the charity, its trustees and advisers</b>	1 - 2
<b>Trustee's report</b>	3 - 8
<b>Independent examiner's report</b>	9 - 10
<b>Statement of financial activities</b>	11
<b>Balance sheet</b>	12
<b>Notes to the financial statements</b>	13 - 24

---

## BOB CHAMPION CANCER TRUST

---

### REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 30 JUNE 2020

---

#### FOUNDER

Professor Sir Michael Peckham MD FRCP FRCR

#### PRESIDENT

Bob Champion, M.B.E.

#### MEDICAL ADVISOR

Professor David Dearnaley

#### VICE PRESIDENTS

Clare Balding, O.B.E.

Willie Carson, O.B.E.

Kristina Cook

David Gower, M.B.E.

Jonjo O'Neill

Greg Rusedski, Esq

Peter Shilton, O.B.E.

Nick Skelton, O.B.E.

#### TRUSTEES

Michael I Cattermole, Esq. (Chairman)

Alex Embiricos

Timothy Fox, Esq.

Andrew Franklin, Esq.

Catherine McAleavey (appointed 2 July 2019)

Catherine Nash

Luke Ponsonby, Esq.

Bridget Rosser

Carolyn Jane Zetter Wells

#### TRUST OFFICERS

Mrs Lucienne Wilkinson

Miss Kate Hall

---

**BOB CHAMPION CANCER TRUST**

---

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS  
(CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2020**

---

**Charity registered number**

1024664

**Principal office**

Unit D Molasses House  
Clove Hitch Quay  
Plantation Wharf  
London  
SW11 3TN

**Secretary**

Mrs. Lucienne Wilkinson

**Chief executive officer**

Mrs. Lucienne Wilkinson

**Accountants**

Ecovis Wingrave Yeats UK Limited  
Waverley House  
7-12 Noel Street  
London  
W1F 8GQ

---

## BOB CHAMPION CANCER TRUST

---

### TRUSTEES' REPORT FOR THE YEAR ENDED 30 JUNE 2020

---

The Trustees present their report and the accounts for the year ended 30th June 2020

#### **Administrative Details**

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year.

Please see page 1 for Trustee details, legal and other administrative detail.

#### **Structure, Governance and Management**

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

#### **Objectives and Activities**

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate and testis.

The Trust opened in collaboration with the Institute of Cancer Research the Bob Champion Research Centre in 2000, which forms part of the first male dedicated cancer research centre, in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust with The University of East Anglia (UEA) opened The Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases.

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or cash donations plus Gift Aid. Income is raised from active social media campaigns and appeals plus an extremely full fundraising calendar, although the Covid -19 pandemic had a disastrous effect on our planned events from March onwards as everything was cancelled. Normally personal sponsorship events, such as competing in running or cycling challenges, are very popular now and raise substantial funds. Other events range from black tie dinners, sports events and walks to coffee mornings and cake sales. Our annual events include our tennis tournament in Battersea Park, a quiz night in London and a charity race day at Plumpton Racecourse in Sussex. The Trust is also heavily involved every year in the Shetland Pony Grand National, the races are held daily during the six days of the International Horse Show at Olympia. Bob Champion is involved during the year helping the children qualify for Olympia and attends every day at Olympia. A biennial Carol Concert, Carols and Champagne, is held at Chelsea Old Church in London. Due to the pandemic as many events as possible have been transferred online and active appeals for assistance on all social media platforms.

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2020**

---

The Trust has produced since 1988 its own, especially commissioned, double sided Christmas card. The card not only raises funds but spreads awareness of the cause and the work of the Trust. The artist/s is selected each year and kindly donates their time and skills in support of the Trust.

Bob Champion attends many of the events himself and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. All events are organised from the office, often with the help of a specific event committee made up from a wide league of friends, volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to help cancer sufferers, their family and friends.

**Achievements and performance**

Each year in the UK of the 48,000 men, who will be diagnosed with prostate cancer, more than 11,000 can expect to die from their disease. Significant improvements, therefore, also need to be made in the treatment of this disease.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'. Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer. This is bad news for sufferers of prostate cancer because cancer genes, once found, can be used to aid treatment and act as targets for new drugs.

A particular problem is the highly variable natural history of prostate cancer causes significant problems in its clinical management. Over-treatment of prostate cancers is a particular concern leading to impotence in a high proportion of cases. This is especially true for PSA screen-detected cancers that are mostly biologically irrelevant and in the absence of treatment would never become life threatening. Conversely, more conservative approaches to disease detection and management may leave potentially aggressive cancers untreated.

In 2019 the Bob Champion Cancer Trust discovery identified a new class of prostate cancer called DESNT, sadly we know that the patients with DESNT cancer have a very poor outcome. Following that breakthrough the Trust is continuing to fund a project aimed at identifying improved clinical markers (biomarkers) which allow radical therapies such as surgery and radiotherapy to be targeted to men with significant cancers, so that the remainder, with biologically unimportant disease, are spared the side-effects of treatment. This project focuses on the use of urine exosomes (small fat covered vesicles given off by cancer cells) to monitor the cancer gene expression. This work forms part of a Global Urine Biomarker initiative, run by Professor Colin Cooper and involving Centres in Canada, USA, UK and Europe, aimed at identifying biomarkers of aggressive prostate cancer.

Professor Cooper, Chair of Cancer Genetics at the University of East Anglia, Associate Dean of Research in the Faculty of Medical Health runs the ICGC Prostate Cancer Project aimed at collecting whole genome DNA sequence from 250 prostate cancer samples including cancers from Shanghai. This is now being expanded to a global initiative called the PanProstate Cancer Group. Professor Cooper is also running a number of Strategic Developments including facilitating translational research between the University and the Norwich Hospital where 5,000 patients are diagnosed with cancer each year including 750 patients with prostate cancer and 10-20 with testicular cancer. These themes form the basis of three projects currently funded by the Trust at UEA.

At the Institute of Cancer Research the Trust's five year grant support in a cancer sequencing project, headed by Professor Ros Eeles, on early on-set prostate cancer – diagnosed at 60 years or less - has been extended for a further two years. This particular study aims to identify targets for personalised therapy and genetic changes in the DNA in order to offer targeted screening to their relatives who harbour these variants.

The Bob Champion post-doctoral fellowship, within Professor Gert Attard team, is divided between the ICR, computational team in the Centre for Evolution and Cancer (CEC) and the University College London Cancer Institute. The work involves whole genome sequencing data from plasma DNA which allows estimation of the amount of tumour material present in a patient's blood. In addition to analysing data from prostate cancer patients participating in several clinical trials, in collaboration with the Royal Marsden Hospital and ICR Urology Unit, which will be extended to patients with bladder or testicular cancer.

TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2020

---

Understandably certain studies were interrupted as scientists and laboratory space was required for Covid-19 research. All projects will be continued as the situation changes.

**Publications and Presentations:-**

Independent Doctors Federation, Malaga, Spain, 20-22 Sept 2019.

Oral Presentation: Eeles R, Prostate Cancer Screening in Men with genetic mutations in breast cancer genes: results from the international IMPACT Study and implications for Practice. Independent Doctors Federation, Malaga, Spain

Joint Meeting of HEBON IMPAHC and VKGN Challenges in Cancer Genetics, Leiden, The Netherlands, 7-8 November 2019.

Oral presentations: Bancroft E. Germline predisposition to prostate cancer – clinical and psychosocial aspects.

Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghorri M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentre S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C; CAMCAP Study Group, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C; TCGA Consortium, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. *Nat Genet.* 2018;50(5):682-692. PMID: 29662167

Lin HY, Huang PY, Chen DT, Tung HY, Sellers TA, Pow-Sang J, Eeles R, Easton D, Kote-Jarai Z, Amin AI, Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Hamdy F, Neal DE, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Batra J, Teixeira MR, Pandha H, Lu YJ; PRACTICAL consortium, Park JY. AA9int: SNP Interaction Pattern Search Using Non-Hierarchical Additive Model Set. *Bioinformatics.* 2018;3(6): 822-833 PMID: 29878078

Mijuskovic M, Saunders EJ, Leongamornlert DA, Wakerell S, Whitmore I, Dadaev T, Cieza-Borrella C, Govindasami K, Brook MN, Haiman CA, Conti DV, Eeles RA, Kote-Jarai Z. Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease. *Br J Cancer.* 2019 Apr;120(8):867. PMID: 29915322

SEPATH: benchmarking the search for pathogens in human tissue whole genome sequence data leads to template pipelines.

Gihawi A, Rallapalli G, Hurst R, Cooper CS, Leggett RM, Brewer DS. *Genome Biol.* 2019 Oct 22;20(1):208. doi: 10.1186/s13059-019-1819-8. PMID: 31639030

The landscape of viral associations in human cancers.

Zapatka M, Borozan I, Brewer DS, Iskar M, Grundhoff A, Alawi M, Desai N, Sultmann H, Moch H; PCAWG Pathogens, Cooper CS, Eils R, Ferretti V, Lichter P; PCAWG Consortium. *Nat Genet.* 2020 Mar;52(3):320-330. doi: 10.1038/s41588-019-0558-9. Epub 2020 Feb 5. PMID: 32025001

Methodology for the at-home collection of urine samples for prostate cancer detection.

Webb M, Manley K, Olivan M, Guldviik I, Palczynska M, Hurst R, Connell SP, Mills IG, Brewer DS, Mills R, Cooper CS, Clark J. *Biotechniques.* 2020 Feb;68(2):65-71. doi: 10.2144/btn-2019-0092. Epub 2019 Nov 29. PMID: 31779479

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2020**

---

A novel stratification framework for predicting outcome in patients with prostate cancer.

Luca BA, Moulton V, Ellis C, Edwards DR, Campbell C, Cooper RA, Clark J, Brewer DS, Cooper CS.Br J Cancer. 2020 May;122(10):1467-1476. doi: 10.1038/s41416-020-0799-5. Epub 2020 Mar 20.PMID: 32203215

Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression.

Luca BA, Moulton V, Ellis C, Connell SP, Brewer DS, Cooper CS.Genes (Basel). 2020 Jul 16;11(7):802. doi: 10.3390/genes11070802.PMID: 32708551

Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.

Connell SP, O'Reilly E, Tuzova A, Webb M, Hurst R, Mills R, Zhao F, Bapat B, Cooper CS, Perry AS, Clark J, Brewer DS.Prostate. 2020 May;80(7):547-558. doi: 10.1002/pros.23968. Epub 2020 Mar 9.PMID: 32153047

Potential for diagnosis of infectious disease from the 100,000 Genomes Project Metagenomic Dataset: Recommendations for reporting results.

Magiorkinis G, Matthews PC, Wallace SE, Jeffery K, Dunbar K, Tedder R, Mbisa JL, Hannigan B, Vayena E, Simmonds P, Brewer DS, Gihawi A, Rallapalli G, Lahnstein L, Fowler T, Patch C, Maleady-Crowe F, Lucassen A, Cooper C.Wellcome Open Res. 2019 Oct 14;4:155. doi: 10.12688/wellcomeopenres.15499.1. eCollection 2019.PMID: 32055707

**PCAWG PAPERS:**

Pan-cancer analysis of whole genomes.

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium.Nature. 2020 Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6. Epub 2020 Feb 5.PMID: 32025007

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S; MC3 Working Group; PCAWG novel somatic mutation calling methods working group, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L; PCAWG Consortium.Nat Commun. 2020 Sep 21;11(1):4748. doi: 10.1038/s41467-020-18151-y.PMID: 32958763

Sex differences in oncogenic mutational processes.

Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N; PCAWG Tumour Subtypes and Clinical Translation, Boutros PC; PCAWG Consortium.Nat Commun. 2020 Aug 28;11(1):4330. doi: 10.1038/s41467-020-17359-2.PMID: 32859912



**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2020**

---

**Financial Review**

The net incoming resources for the year were £37,675 (2019: *loss of £87,331*) which include a surplus on fundraising events of £119,689 (2019: *£ 131,689*) and dividends received of £50,960 (2019: *£60,754*). In addition, unrealised gain on investments was £26,401 (2019: *£8,708*).

The Trustees are satisfied that the charity's funds are available and adequate to fulfil its obligations in relation to their commitments.

The Declaration of Trust, signed on the 29th June 1993, states that "any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially."

It is the policy of the charity to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

**Plans for the Future**

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at The Institute of Cancer Research and The Norwich Medical Research Park at UEA. To establish a clinical test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officers of the Charity, donations and legacies and the interest from the investment funds if required.

**Statement of Trustees' Responsibilities**

The trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

The trustees are required to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and the incoming resources and application of resources, including the net income or expenditure, for the year. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Companies Act. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

---

**BOB CHAMPION CANCER TRUST**

---

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2020**

---

In so far as the trustees are aware:

- there is no relevant information of which the charity's independent examiner is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves.

.

07 April 2021

Approved by order of the members of the board of Trustee on

and signed on their behalf by:

*Mike Cattermole*

*Tim Fox*

**Michael Cattermole**  
Trustee

**Timothy Fox**  
Trustee

---

## BOB CHAMPION CANCER TRUST

---

### INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 30 JUNE 2020

---

#### **Independent Examiner's Report to the Trustees of Bob Champion Cancer Trust ('the charity')**

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 30 June 2020.

This report is made solely to the charity's Trustees, as a body, in accordance with section 145 of the Charities Act 2011 and regulations made under section 154 of that Act. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees, as a body, for our work or for this report.

#### **Responsibilities and Basis of Report**

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

#### **Independent Examiner's Statement**

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. We confirm that we are qualified to undertake the examination because we are a member of ICAEW, which is one of the listed bodies.

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

---

**BOB CHAMPION CANCER TRUST**

---

**INDEPENDENT EXAMINER'S REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2020**

---

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached

*Stuart Hinds*

Signed:

Dated: 07 April 2021

Stuart Hinds

ACA

for and on behalf of  
Ecovis Wingrave Yeats UK Limited

Waverley House  
7-12 Noel Street  
London  
W1F 8GQ

**BOB CHAMPION CANCER TRUST**

**STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 30 JUNE 2020**

	Note	Unrestricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
<b>Income from:</b>				
Donations and legacies	2	26,380	26,380	55,351
Other charitable activities	3	217,564	217,564	297,347
Investments	4	50,975	50,975	61,030
Other income	5	1,988	1,988	-
<b>Total income</b>		<b>296,907</b>	<b>296,907</b>	<b>413,728</b>
<b>Expenditure on:</b>				
Raising funds		97,875	97,875	165,658
Charitable activities:				
Research grants		84,225	84,225	233,366
Support costs		93,693	93,693	100,090
Governance		9,840	9,840	10,653
<b>Total expenditure</b>		<b>285,633</b>	<b>285,633</b>	<b>509,767</b>
Net gains on investments		26,401	26,401	8,708
<b>Net movement in funds before other recognised gains</b>		<b>37,675</b>	<b>37,675</b>	<b>(87,331)</b>
<b>Net movement in funds</b>		<b>37,675</b>	<b>37,675</b>	<b>(87,331)</b>
<b>Reconciliation of funds:</b>				
Total funds brought forward		1,517,790	1,517,790	1,605,121
Net movement in funds		37,675	37,675	(87,331)
<b>Total funds carried forward</b>		<b>1,555,465</b>	<b>1,555,465</b>	<b>1,517,790</b>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 13 to 24 form part of these financial statements.

**BOB CHAMPION CANCER TRUST**

**BALANCE SHEET  
AS AT 30 JUNE 2020**

	Note	2020 £	2019 £
<b>Fixed assets</b>			
Tangible assets	9	3,268	4,358
Investments	10	1,448,749	1,591,208
		<u>1,452,017</u>	<u>1,595,566</u>
<b>Current assets</b>			
Debtors	11	6,674	13,274
Cash at bank and in hand		138,810	45,474
		<u>145,484</u>	<u>58,748</u>
Creditors: amounts falling due within one year	12	(42,036)	(136,524)
<b>Net current assets / liabilities</b>		<u>103,448</u>	<u>(77,776)</u>
<b>Total net assets</b>		<u><u>1,555,465</u></u>	<u><u>1,517,790</u></u>
<b>Charity funds</b>			
Restricted funds		-	-
Unrestricted funds		1,555,465	1,517,790
<b>Total funds</b>		<u><u>1,555,465</u></u>	<u><u>1,517,790</u></u>

The financial statements were approved and authorised for issue by the Trustees on 07 April 2021 and signed on their behalf by:

*Mike Cattermole*

*Tim Fox*

**Michael Cattermole**  
Trustee

**Timothy Fox**  
Trustee

The notes on pages 13 to 24 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2020**

---

**1. Accounting policies**

**1.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Bob Champion Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

**1.2 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustee in furtherance of the general objectives of the charity and which have not been designated for other purposes.

**1.3 Income**

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of the Friends is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the charity which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2020**

---

**1. Accounting policies (continued)**

**1.4 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in charitable activities that raise funds.

Charitable activities and Governance costs are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity apportioned to charitable activities.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

**1.5 Going concern**

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts.

**1.6 Government grants**

Government grants are accounted under the accruals model as permitted by the Charities SORP. During the year the Charity has received governmental support through the Coronavirus Job Retention Scheme. The government grants received in the year are of a revenue nature and are recognised in the Statement of Financial Activities in the same period as the related expenditure.



**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2020**

---

**1. Accounting policies (continued)**

**1.7 Tangible fixed assets and depreciation**

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of financial activities.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer equipment	- 25% reducing balance
--------------------	------------------------

**1.8 Investments**

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

**1.9 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

**1.10 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**1.11 Cash at bank and in hand**

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**1.12 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2020**

---

**1. Accounting policies (continued)**

**1.13 Financial instruments**

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**1.14 Pensions**

The charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the charity to the fund in respect of the Year.

**1.15 Critical accounting estimates and areas of judgement**

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

**1.16 Basis of non-conclusion**

In the opinion of the Trustees, the charity and its subsidiary undertakings comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

# BOB CHAMPION CANCER TRUST

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

### 2. Income from donations and legacies

	Unrestricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
League of Friends	10,050	<b>10,050</b>	3,480
Memorial	6,230	<b>6,230</b>	44,512
Other	10,100	<b>10,100</b>	7,359
<b>Total</b>	<b>26,380</b>	<b>26,380</b>	<b>55,351</b>

In both the current year and prior year all income from donations and legacies was in relation to unrestricted funds.

### 3. Activities for generating funds

	Unrestricted funds 2020 £	Total funds 2020 £	Total funds 2019 £
Carols and Champagne	-	-	64,162
Shetland Pony Grand National	38,258	<b>38,258</b>	38,811
Tennis tournament	414	<b>414</b>	16,660
Champions Wilberry race	-	-	86,602
Chepstow Jump Legends	-	-	12,173
Christmas Season	29,251	<b>29,251</b>	35,447
General fundraising	37,809	<b>37,809</b>	43,492
Plumpton Raceday	111,832	<b>111,832</b>	-
<b>Total</b>	<b>217,564</b>	<b>217,564</b>	<b>297,347</b>

---

**BOB CHAMPION CANCER TRUST**

---

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2020**

---

**4. Investment income**

	<b>Unrestricted funds 2020 £</b>	<b>Total funds 2020 £</b>	<i>Total funds 2019 £</i>
Listed securities	50,960	<b>50,960</b>	60,754
Bank deposits	15	<b>15</b>	276
<b>Total</b>	<u>50,975</u>	<u><b>50,975</b></u>	<u>61,030</u>

In both the current year and prior year all investment income was in relation to unrestricted funds.

**5. Other income**

	<b>Unrestricted funds 2020 £</b>	<b>Total funds 2020 £</b>	<i>Total funds 2019 £</i>
Government grants	<u>1,988</u>	<u><b>1,988</b></u>	<u>-</u>

Government grant income in the year ended 30 June 2019 was £Nil.

## BOB CHAMPION CANCER TRUST

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

#### 6. Research grants

	Grants to Institutions 2020 £	Total funds 2020 £	Total funds 2019 £
Building project - The Bob Champion Research and Education Building at the University of East Anglia	-	-	50,000
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	23,056	<b>23,056</b>	75,000
Bob Champion Cancer Trust Post Doctoral fellowship grant - ICR	28,030	<b>28,030</b>	62,366
Professor Colin Cooper grant - UEA	33,139	<b>33,139</b>	46,000
<b>Total</b>	<b>84,225</b>	<b>84,225</b>	233,366

The Bob Champion Research and Education Building is based on the Norwich Research Park and operated by the University of East Anglia in partnership with the Norfolk & Norwich University Hospital. This centre, opened February 2015, provides state-of-the-art laboratories for researchers, plus a unique bio-bank facility to store DNA and tissue samples as well as undergraduate and post graduate education. The trust has pledged £750,000 towards the project payable over a five year period, 2015-2019. As at 30 June 2020, £750,000 (2019 - £682,500) has been donated towards the project.

Professor Ros Eeles, Prostate Cancer Sequencing Project at the ICR, commenced in August 2019 at cost of £282,509 over the three year grant period. Due to Covid-19, this grant has been put on hold as the ICR focused efforts on research of the virus. However, the grant will resume once the laboratory at the ICR has returned to normal functions.

Dr Marianna Buongiorno, appointed in November 2017 for three years at a cost of £188,000, held the position of the Bob Champion Post - doctoral fellowship within Dr Gert Attard's team at the ICR. In the prior year Dr Mahedi Hassan replaced Dr Marianna Buongiorno in the Bob Champion Post - Doctoral Fellowship within Dr Gert Attard's team at the ICR. Dr Gert Attard is Affiliate Team Leader for the Centre for Evolution and Cancer at the ICR and Team Leader of Treatment Resistance Research Group at UCL. Due to Covid-19, this grant has been put on hold as the ICR has focused efforts on research of the virus. However, the grant will resume once the laboratory at the ICR has returned to normal functions.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded in January 2020 for two years at a cost of £80,000. Professor Cooper is Professor of Cancer Genetics and Associate Dean of Research at UEA.

# BOB CHAMPION CANCER TRUST

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2020

### 7. Analysis of expenditure by activities

	Grant funding of activities 2020 £	Support costs 2020 £	Total funds 2020 £	Total funds 2019 £
Premises costs	-	13,142	<b>13,142</b>	13,344
Other costs	-	9,232	<b>9,232</b>	12,399
Personnel costs	-	71,319	<b>71,319</b>	74,347
Governance costs	-	9,840	<b>9,840</b>	10,653
Professor Rosalind Eeles grant - Institute of Cancer Research	23,056	-	<b>23,056</b>	75,000
Dr. Attard grant	28,030	-	<b>28,030</b>	62,366
Professor Colin Cooper grant - UEA	33,139	-	<b>33,139</b>	46,000
Building project at UEA - The Bob Champion Research and Education Building	-	-	-	50,000
<b>Total</b>	<b>84,225</b>	<b>103,533</b>	<b>187,758</b>	<b>344,109</b>

### 8. Staff costs

	2020 £	2019 £
Wages and salaries	<b>65,478</b>	69,078
Social security costs	<b>3,909</b>	3,869
Contribution to defined contribution pension schemes	<b>1,932</b>	1,400
	<b>71,319</b>	<b>74,347</b>

The average number of persons employed by the charity during the year was as follows:

	2020 No.	2019 No.
Employees	<b>2</b>	2

No employee received remuneration amounting to more than £60,000 in either year.

The total employment benefits of key management personnel were £50,250 (2019 - £50,520).

---

**BOB CHAMPION CANCER TRUST**

---

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2020**

---

**9. Tangible fixed assets**

	Computer equipment £
<b>Cost or valuation</b>	
At 1 July 2019	6,782
At 30 June 2020	<u>6,782</u>
<b>Depreciation</b>	
At 1 July 2019	2,424
Charge for the Year	1,090
At 30 June 2020	<u>3,514</u>
<b>Net book value</b>	
At 30 June 2020	<u><u>3,268</u></u>
At 30 June 2019	<u><u>4,358</u></u>

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2020**

**10. Fixed asset investments**

	Investments in subsidiary companies £	Listed investments £	Total £
<b>Cost or valuation</b>			
At 1 July 2019	2	1,591,206	1,591,208
Additions	-	1,600,000	1,600,000
Disposals	-	(1,768,860)	(1,768,860)
Revaluations	-	26,401	26,401
<b>At 30 June 2020</b>	<b>2</b>	<b>1,448,747</b>	<b>1,448,749</b>
<b>Net book value</b>			
<b>At 30 June 2020</b>	<b>2</b>	<b>1,448,747</b>	<b>1,448,749</b>
<i>At 30 June 2019</i>	<i>2</i>	<i>1,591,206</i>	<i>1,591,208</i>

**Subsidiary undertakings**

The following was a subsidiary undertaking of the charity:

Name	Holding
Aldaniti Trading Company Limited	100%

The financial results of the subsidiary for the year were:

Name	Aggregate of share capital and reserves £
Aldaniti Trading Company Limited	2

During year, the charity fully disposed of investments held with M&G Securities. An amount of £1,600,000 was invested in a COIF Charities Investment Fund managed by CCLA Investment Management Limited. At the year end CCLA, an investment management company external to the charity, valued the units held by the charity at £1,448,747. This valuation was made on the basis of the value of the units on the open market in which they are traded. Any gain or loss is included in the Statement of Financial Activities.

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004 and has not traded since. On this date its trade and assets were transferred to the charity.



**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2020**

**11. Debtors**

	2020 £	2019 £
<b>Due within one year</b>		
Other debtors	4,998	-
Prepayments and accrued income	1,676	13,274
	<u>6,674</u>	<u>13,274</u>

**12. Creditors: Amounts falling due within one year**

	2020 £	2019 £
Accruals - grants	12,325	94,801
Amounts owed to group undertakings	2	2
Other taxation and social security	2,598	1,176
Other creditors	272	443
Accruals and deferred income	26,839	40,102
	<u>42,036</u>	<u>136,524</u>

**13. Financial instruments**

	2020 £	2019 £
<b>Financial assets</b>		
Financial assets measured at fair value through income and expenditure	<u>1,448,747</u>	<u>1,591,206</u>

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

**14. Pension commitments**

The charity operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,932 (2019 - £1,400). Contributions totalling £272 (2019 - £328) were payable to the fund at the balance sheet date and are included in creditors.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2020**

---

**15. Related party transactions**

During the year, the charity paid £28,630 (2019 - £31,766) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £4,960 (2019 - £7,634). Bob Champion's retainer has been approved by the Charity Commission.